We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis. Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.
Ask ADVFN Intelligence (AI)
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of...
INTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology...
BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant...
SOUTH SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that Keith Cummings, M.D., Chief Financial Officer, and Greg Cosgrove, M.D. FCCP...
INTEGRIS-PSC to be featured in an oral presentation on Monday, November 18 SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage...
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.65 | -4.74452554745 | 13.7 | 14.04 | 11.76 | 872056 | 12.58877794 | CS |
| 4 | -1.16 | -8.16326530612 | 14.21 | 16.1 | 11.76 | 466353 | 13.64127807 | CS |
| 12 | 0.03 | 0.230414746544 | 13.02 | 16.1 | 10.22 | 418658 | 13.02746251 | CS |
| 26 | -1.96 | -13.0579613591 | 15.01 | 16.1 | 10.22 | 480046 | 12.61554448 | CS |
| 52 | -1.31 | -9.12256267409 | 14.36 | 19.62 | 10.22 | 443549 | 13.96150527 | CS |
| 156 | -2.305 | -15.0113969391 | 15.355 | 36.64 | 3.965 | 621502 | 19.33813165 | CS |
| 260 | -9.45 | -42 | 22.5 | 43.92 | 3.965 | 457921 | 20.05703191 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
